Rubius Therapeutics, Inc. (RUBY)
Total Valuation
RUBY has a market cap or net worth of $1.80 million. The enterprise value is -$11.86 million.
| Market Cap | 1.80M |
| Enterprise Value | -11.86M |
Important Dates
The last earnings date was Friday, March 10, 2023, before market open.
| Last Earnings Date | Mar 10, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
RUBY has 90.48 million shares outstanding. The number of shares has increased by 0.43% in one year.
| Shares Outstanding | 90.48M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | -0.07% |
| Owned by Insiders (%) | 5.50% |
| Owned by Institutions (%) | 67.16% |
| Float | 46.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.13 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.54 |
| Quick Ratio | n/a |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -133.10%.
| Return on Equity (ROE) | -133.10% |
| Return on Assets (ROA) | -87.30% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$19.96M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.65% in the last 52 weeks. The beta is 2.51, so RUBY's price volatility has been higher than the market average.
| Beta (1Y) | 2.51 |
| 52-Week Price Change | -99.65% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.47 |
| Average Volume (30 Days) | 4,535,714 |
Short Selling Information
The latest short interest is 1.53 million, so 1.69% of the outstanding shares have been sold short.
| Short Interest | 1.53M |
| Short Previous Month | 1.87M |
| Short % of Shares Out | 1.69% |
| Short % of Float | 3.26% |
| Short Ratio (days to cover) | 0.49 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -178.45M |
| Pretax Income | -179.67M |
| Net Income | -179.67M |
| EBITDA | -169.85M |
| EBIT | -175.80M |
| Earnings Per Share (EPS) | -$1.99 |
Balance Sheet
The company has $14.87 million in cash and $1.10 million in debt, giving a net cash position of $13.77 million or $0.15 per share.
| Cash & Cash Equivalents | 14.87M |
| Total Debt | 1.10M |
| Net Cash | 13.77M |
| Net Cash Per Share | $0.15 |
| Equity / Book Value | 15.13M |
| Book Value Per Share | 0.17 |
| Working Capital | 12.26M |
Cash Flow
In the last 12 months, operating cash flow was -$150.14 million and capital expenditures -$5.30 million, giving a free cash flow of -$155.45 million.
| Operating Cash Flow | -150.14M |
| Capital Expenditures | -5.30M |
| Free Cash Flow | -155.45M |
| FCF Per Share | -$1.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RUBY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -9,455.39% |
| FCF Yield | -8,180.75% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
Analyst Forecast
The average price target for RUBY is $1.02, which is 5,025.63% higher than the current price. The consensus rating is "Sell".
| Price Target | $1.02 |
| Price Target Difference | 5,025.63% |
| Analyst Consensus | Sell |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |